Aura Biosciences Stock Performance
| AURA Stock | USD 7.49 0.12 1.63% |
The firm shows a Beta (market volatility) of 0.69, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Aura Biosciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Aura Biosciences is expected to be smaller as well. At this point, Aura Biosciences has a negative expected return of -0.3%. Please make sure to confirm Aura Biosciences' value at risk, rate of daily change, relative strength index, as well as the relationship between the kurtosis and market facilitation index , to decide if Aura Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Aura Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.63 | Five Day Return (1.45) | Year To Date Return (9.32) | Ten Year Return (49.39) | All Time Return (49.39) |
1 | Aura Announces Bluestone Securityholders Approval of Transaction | 12/19/2024 |
2 | Long Focus Capital Management, LLC Increases Stake in Aura Biosc - GuruFocus.com | 01/03/2025 |
3 | Baylor Genetics to Integrate with Epic Aura to Enhance Efficiency and Deliver Genetic Testing Results to Hospitals and Health Systems | 01/13/2025 |
4 | Disposition of 1001 shares by Amy Elazzouzi of Aura Biosciences at 7.6715 subject to Rule 16b-3 | 01/21/2025 |
5 | This Insider Has Just Sold Shares In Aura Biosciences | 01/24/2025 |
6 | Acquisition by Mattessich Antony C. of 10500 shares of Aura Biosciences subject to Rule 16b-3 | 01/27/2025 |
7 | Aura Biosciences, Inc. Short Interest Update | 01/31/2025 |
8 | Acquisition by Amy Elazzouzi of 29760 shares of Aura Biosciences at 7.68 subject to Rule 16b-3 | 02/03/2025 |
9 | Q1 Earnings Forecast for AURA Issued By Leerink Partnrs | 02/07/2025 |
10 | Clear Capitals Appraisal Underwriting Risk Analyzer, AURA, now Available Through ICE Mortgage Technologys Encompass Platform | 02/13/2025 |
11 | Disposition of 20221 shares by De Los Pinos Elisabet of Aura Biosciences at 7.7541 subject to Rule 16b-3 | 02/18/2025 |
12 | Aura Unites with Boston Childrens Hospital to Address the Role of Technology in the Crisis of Wellbeing Among American Children | 02/26/2025 |
| Begin Period Cash Flow | 122.4 M |
Aura |
Aura Biosciences Relative Risk vs. Return Landscape
If you would invest 914.00 in Aura Biosciences on December 2, 2024 and sell it today you would lose (165.00) from holding Aura Biosciences or give up 18.05% of portfolio value over 90 days. Aura Biosciences is currently does not generate positive expected returns and assumes 2.4417% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Aura, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aura Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aura Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aura Biosciences, and traders can use it to determine the average amount a Aura Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1216
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | AURA |
Estimated Market Risk
| 2.44 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.12 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Aura Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aura Biosciences by adding Aura Biosciences to a well-diversified portfolio.
Aura Biosciences Fundamentals Growth
Aura Stock prices reflect investors' perceptions of the future prospects and financial health of Aura Biosciences, and Aura Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aura Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 219.59 M | ||||
| Shares Outstanding | 49.95 M | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (83.7 M) | ||||
| Net Income | (76.41 M) | ||||
| Cash And Equivalents | 122.13 M | ||||
| Cash Per Share | 4.17 X | ||||
| Total Debt | 19.56 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 21.97 X | ||||
| Book Value Per Share | 3.51 X | ||||
| Cash Flow From Operations | (63.85 M) | ||||
| Earnings Per Share | (1.73) X | ||||
| Market Capitalization | 374.14 M | ||||
| Total Asset | 255.07 M | ||||
| Retained Earnings | (287.31 M) | ||||
| Working Capital | 219.44 M | ||||
About Aura Biosciences Performance
By analyzing Aura Biosciences' fundamental ratios, stakeholders can gain valuable insights into Aura Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aura Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aura Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.39) | (0.37) |
Things to note about Aura Biosciences performance evaluation
Checking the ongoing alerts about Aura Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aura Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aura Biosciences generated a negative expected return over the last 90 days | |
| Net Loss for the year was (76.41 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aura Biosciences currently holds about 122.13 M in cash with (63.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.17. | |
| Aura Biosciences has a frail financial position based on the latest SEC disclosures | |
| Over 83.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Crinetics Pharmaceuticals Expected to Announce Quarterly Earnings on Thursday |
- Analyzing Aura Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aura Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Aura Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aura Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aura Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aura Biosciences' stock. These opinions can provide insight into Aura Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aura Stock analysis
When running Aura Biosciences' price analysis, check to measure Aura Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aura Biosciences is operating at the current time. Most of Aura Biosciences' value examination focuses on studying past and present price action to predict the probability of Aura Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aura Biosciences' price. Additionally, you may evaluate how the addition of Aura Biosciences to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |